FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

David Hollenback

Research Profile

Chemicals & Drugs

Anatomy

Tumor Cell Line

Concepts & Ideas

Disorders

Congenital Generalized Lipodystrophy

Procedures

Phenomena

Phosphorylation

Physiology

Living Beings

Mouse

Co-author Network

Publications

TOP 3
Sasha Taleban; Heather T Carew; Helén L Dichek; Samir S Deeb; David Hollenback; David S Weigle; David E Cummings; John D Brunzell
Energy balance in congenital generalized lipodystrophy type I.
Paul La Rosée; Taiping Jia; Shadmehr Demehri; Nicolai Härtel; Peter de Vries; Lynn Bonham; David Hollenback; Jack W Singer; Junia V Melo; Brian J Druker; Michael W N Deininger
Antileukemic activity of lysophosphatidic acid acyltransferase-beta inhibitor CT32228 in chronic myelogenous leukemia sensitive and resistant to imatinib.
Mike Douvas; Karen N Hogan; YanShan Ji; David Hollenback; Lynn Bonham; Jack W Singer; Beverly S Mitchell
Effect of lysophosphatidic acid acyltransferase-beta inhibition in acute leukemia.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of David Hollenback (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2008: Sasha Taleban; Heather T Carew; Helén L Dichek; Samir S Deeb; David Hollenback; David S Weigle; David E Cummings; John D Brunzell
Energy balance in congenital generalized lipodystrophy type I.
Metabolism: clinical and experimental 2008;57(8):1155-61.
2006: Paul La Rosée; Taiping Jia; Shadmehr Demehri; Nicolai Härtel; Peter de Vries; Lynn Bonham; David Hollenback; Jack W Singer; Junia V Melo; Brian J Druker; Michael W N Deininger
Antileukemic activity of lysophosphatidic acid acyltransferase-beta inhibitor CT32228 in chronic myelogenous leukemia sensitive and resistant to imatinib.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(21):6540-6.
2006: Mike Douvas; Karen N Hogan; YanShan Ji; David Hollenback; Lynn Bonham; Jack W Singer; Beverly S Mitchell
Effect of lysophosphatidic acid acyltransferase-beta inhibition in acute leukemia.
Leukemia research 2006;30(8):1027-36.
2006: David Hollenback; Lynn Bonham; Laura Law; Eddie Rossnagle; Lisa Romero; Heather Carew; Christopher K Tompkins; David W Leung; Jack W Singer; Thayer White
Substrate specificity of lysophosphatidic acid acyltransferase beta -- evidence from membrane and whole cell assays.
Journal of lipid research 2006;47(3):593-604.
2005: Feng Hong; David Hollenback; Jack W Singer; Peter Klein
Diamino-C,N-diarylpyridine positional isomers as inhibitors of lysophosphatidic acid acyltransferase-beta.
Bioorganic & medicinal chemistry letters 2005;15(21):4703-7.
2005: John M Pagel; Christian Laugen; Lynn Bonham; Robert C Hackman; David M Hockenbery; Rama Bhatt; David Hollenback; Heather Carew; Jack W Singer; Oliver W Press
Induction of apoptosis using inhibitors of lysophosphatidic acid acyltransferase-beta and anti-CD20 monoclonal antibodies for treatment of human non-Hodgkin's lymphomas.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(13):4857-66.
2003: Michael Coon; Alexey Ball; Jeannine Pound; Sophe Ap; David Hollenback; Thayer White; John Tulinsky; Lynn Bonham; Deborah K Morrison; Robert Finney; Jack W Singer
Inhibition of lysophosphatidic acid acyltransferase beta disrupts proliferative and survival signals in normal cells and induces apoptosis of tumor cells.
Molecular cancer therapeutics 2003;2(10):1067-78.
2003: Lynn Bonham; David W Leung; Thayer White; David Hollenback; Peter Klein; John Tulinsky; Michael Coon; Peter de Vries; Jack W Singer
Lysophosphatidic acid acyltransferase-beta: a novel target for induction of tumour cell apoptosis.
Expert opinion on therapeutic targets 2003;7(5):643-61.